gene_symbol
ERBB2
hgnc_id
HGNC:3430
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
DIRECT
cytotoxicity_mechanism
The anti-HER2 antibody–drug conjugate binds HER2, is internalized, and releases the topoisomerase I inhibitor deruxtecan in lysosomes, causing DNA damage, cell-cycle arrest, and apoptosis; Fc-mediated ADCC and a bystander effect can also contribute.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Target of trastuzumab component; effective even in HER2-low expression (IHC 1+ or 2+/ISH−)
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06231693
disease_id_num_tar_ref
6146
drug_id_num_tar_ref
16658